Latest Filings

Issuer Activity

Insider Overview :: iCo Therapeutics Inc. (V:ICO) [?]
Business Focus: Biotechnology & Medical Research
Recent Price for ICO
CAD 0.345 -0.01 (-1.45%)
TSXV Delayed 15 minutes
May 17 1559 EDT
1-Day High 52-Week High P/E 1-Day Volume Mkt Cap ($Mil)
N/A 0.890 0.0 N/A 18.88
1-Day Low 52-Week Low Yield Avg. Volume  
N/A 0.245 0.0% 329,473  
Log in or sign up for a free account to add this stock to your watch list.
Holdings trends & enhanced charts available in PDF report. Click here for details »
Latest 10 SEDI filings (by transaction date) for ICO within the last 6 months [?]
Amended Filing
As of 11:59pm ET May 18th, 2013
Filing
Date 		Transaction
Date 		Insider Name Ownership
Type 		Securities Nature of transaction # or value acquired or disposed of Price
May 10/13 May 10/13 Meekison, William John Control or Direction Common Shares 10 - Acquisition in the public market 10,000 $0.315
May 10/13 May 10/13 Meekison, William John Direct Ownership Common Shares 10 - Acquisition in the public market 10,000 $0.295
Feb 25/13 Feb 22/13 Meekison, William John Direct Ownership Options 51 - Exercise of options -100,000 $0.290
Feb 25/13 Feb 22/13 Meekison, William John Direct Ownership Common Shares 51 - Exercise of options 100,000 $0.290
Feb 25/13 Feb 22/13 Meekison, William John Direct Ownership Common Shares 10 - Disposition in the public market -200,000 $0.550
Feb 25/13 Feb 22/13 Meekison, William John Indirect Ownership Warrants 54 - Exercise of warrants -350,000  
Feb 25/13 Feb 22/13 Meekison, William John Control or Direction Common Shares 54 - Exercise of warrants 350,000 $0.300
Feb 25/13 Feb 22/13 Meekison, William John Control or Direction Common Shares 10 - Disposition in the public market -300,000 $0.550
Jan 27/13 Jan 22/13 Janzen, Doug Direct Ownership Options 50 - Grant of options 25,000 $0.730
Jan 23/13 Jan 22/13 Jarosz, William Wasyl Direct Ownership Options 50 - Grant of options 100,000 $0.730
Sign up for an account or login above to see all SEDI filings within the past 6 months.
Latest 10 SEDI filings (by filing date) for ICO within the last 6 months [?]
Amended Filing
As of 11:59pm ET May 18th, 2013
Filing
Date 		Transaction
Date 		Insider Name Ownership
Type 		Securities Nature of transaction # or value acquired or disposed of Price
May 10/13 May 10/13 Meekison, William John Control or Direction Common Shares 10 - Acquisition in the public market 10,000 $0.315
May 10/13 May 10/13 Meekison, William John Direct Ownership Common Shares 10 - Acquisition in the public market 10,000 $0.295
Feb 25/13 Feb 22/13 Meekison, William John Direct Ownership Options 51 - Exercise of options -100,000 $0.290
Feb 25/13 Feb 22/13 Meekison, William John Direct Ownership Common Shares 51 - Exercise of options 100,000 $0.290
Feb 25/13 Feb 22/13 Meekison, William John Direct Ownership Common Shares 10 - Disposition in the public market -200,000 $0.550
Feb 25/13 Feb 22/13 Meekison, William John Indirect Ownership Warrants 54 - Exercise of warrants -350,000  
Feb 25/13 Feb 22/13 Meekison, William John Control or Direction Common Shares 54 - Exercise of warrants 350,000 $0.300
Feb 25/13 Feb 22/13 Meekison, William John Control or Direction Common Shares 10 - Disposition in the public market -300,000 $0.550
Jan 27/13 Jan 22/13 Janzen, Doug Direct Ownership Options 50 - Grant of options 25,000 $0.730
Jan 23/13 Jan 22/13 Jarosz, William Wasyl Direct Ownership Options 50 - Grant of options 100,000 $0.730
Sign up for an account or login above to see all SEDI filings within the past 6 months.
Sign up for an account or login above to see the past 6 months of SEDI filings sorted by insider.
No Markers (TSX Insider Summaries) for ICO on May 17, 2013 [?]
To view marker data for the past week, sign up for an account or log in above.
To view more history, sign up for an account at inkresearch.com
Sector:  Healthcare Industry:  Biotechnology & Medical Research
Key People
William W. Jarosz
Independent Chairman of the Board 		Andrew J. Rae
President, Chief Executive Officer, Director 		W. John Meekison
Chief Financial Officer, Corporate Secretary
Jeremy S. Ono
Chief Scientific Officer 		Peter Hnik
Chief Medical Officer 		 
Company Contact
Address: 760-777 Hornby Street
VANCOUVER BC V6Z 1S4
Tel: 1-604-6029414
Website: www.icotherapeutics.com
IR: www.icotherapeutics.com/investor_relations
Business Overview
iCo Therapeutics Inc. (iCo) is a Canadian biotechnology company focused on the identification, development and commercialization of drug candidates to treat sight threatening and life threatening diseases through a business model. The Company focuses on in-licensing drug candidates with a clinical history and redose, reformulate and develop drug candidates for the treatment of sight-threatening conditions, such as diabetic macular edema (DME) and severe allergic conjunctivitis and life threatening diseases such as severe systemic fungal infections. Its in-license three product candidates are iCo-007, iCo-008 and an Oral Amphotericin B Delivery System (formerly iCo-009), which is under development. On February 22, 2011, iCo announced the completion of Phase II clinical supply manufacturing of ICo-007. On September 26, 2011, iCo announced a research collaboration agreement with Juvenile Diabetes Research Foundation (JDRF) for the Phase II clinical trial investigation of iCo-007 in DME.
Competitors with Recent Insider Filings
QLT (T:QLT)
EnWave (V:ENW)
Sirona Biochem (V:SBM)
 
iCo Therapeutics Inc. Insider Report Only $20.00